Alberto Fernández has confirmed that he is negotiating the purchase of Cuban vaccines despite the objections of international science

President Alberto Fernandez started negotiations with his Cuban counterpart, Miguel Diaz Canel, to access Soberana 2 and Abdalpa, the scientific developments against the coronavirus that the National Academy of Medicine of Venezuela has qualified as “experimental products whose composition, harmlessness or effectiveness are not known”. “These are not real vaccines,” the entity warned.

“I was talking with the president of Cuba, with engineer Díaz Canel. Cuba has done a job that all scientists consider marvelous, very important, by developing a vaccine called Sovereign, which has two versions, which is in phase 3, ”assured the Argentine president.

“I asked him what his production capacity was, he told me about the difficulties he had to work and I offered to work together so that all of Latin America could have access to a vaccine.Alberto Fernández added on radio 10.

The Academia Nacional de Medicina de Venezuela alertó en los últimos días sobre la falta de información fehaciente sobre el posible inoculante luego de que el dictador Nicolás Maduro anunciara that in Venezuela will be produced for mes 2 millones de dosis de Abdalá, uno de los candidateos cubanos contra disease.

“We signed an agreement to produce in our laboratories (…) 2 million vaccines per month of the Abdalá vaccine, already there for the month of August, September, approximately”, said the Chavist dictator. At the end of March, he said his regime intended to be able to start administering the vaccine in July despite the fact that the trials – part of which are under development in Venezuela – have not been completed or approved.

He also assured that the country will sign agreements with China, Russia and “other countries” to produce other vaccines against COVID-19.

In this regard, the Academy pointed out that “There is an urgent need for a national COVID-19 vaccination plan that will serve as a fundamental support for all the initiatives necessary to ensure the vaccination of approximately 15 million Venezuelans.”

New vaccine shipment to Argentina

A few days after the different provinces and the city of Buenos Aires were out of stock to continue the vaccination campaign, the government confirmed the arrival of a new batch for the next few days. On the weekend they will arrive in the country 864 thousand doses of AstraZeneca vaccine as part of Covax mechanism.

This was announced by the executive, who detailed that the doses will arrive in Argentina on the flight KL701 of the airline KLM who will land at the airport Ezeiza at 6 a.m. on Sunday.

This week, Infobae I had anticipated that Argentina faces worst-case scenario if new shipment does not materialize: an exponential increase in daily coronavirus infections and the vaccination campaign suspended for lack of doses.

High efficiency

AstraZeneca’s COVID-19 vaccine is 79% effective in preventing disease and does not increase the risk of blood clots, the biotech company said on Monday, following its phase III efficacy trials in states -United.

The vaccine was also 80% effective for those over 65, according to published scientific data. Several countries had suspended the drug from the elderly due to a lack of data in older participants in previous trials and the risk of recorded thrombosis.

Although the AstraZeneca vaccine has been licensed in more than 50 countries around the world, it has yet to be given the green light in the United States. The new study included 30,000 volunteers, of whom 20,000 received the vaccine and the rest a placebo.

The vaccine was 79% effective in preventing symptomatic COVID-19 and 100% effective in preventing severe cases and hospitalizations. The researchers noted that the vaccine had been effective in all age groups, including the elderly, which had not been established in previous studies in other countries.

KEEP READING: